Burcon Nutrascience Stock Earnings Reports

Burcon reports Q1 FY2026 results and emphasizes execution progress after integrating its proprietary protein extraction technology into the Galesburg, Illinois production facility (operated with an Alliance Partner). Key milestones include the first commercial production of Peazazz (pea protein), subsequent commercial production and launch of fava protein, completion of a $6.8 million multiyear (5-year) production agreement that provides recurring quarterly production revenue and baseload for the facility, a successful rights offering and 20-for-1 share consolidation. Revenue for the quarter was $342k. Management highlights a strong and expanding customer funnel (samples → bag → pallet → commercial purchases), notable customer excitement generated at the IFT trade show (including early traction in plant-based cheese applications), and plans to progress through its product portfolio (canola, sunflower, etc.) with the goal of $1M–$3M revenue in 2025, double-digit revenue growth in 2026 and cash-flow positive in 2026. Company strategy: continue to execute commercial-scale production, grow recurring revenue, and later scale via licensing/partnerships. Management says tariffs are not expected to impact the business and current balance sheet supports the plan, though they remain open to evaluating financing only if new opportunities arise.